General Information:

Id: 1,977
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
article
Reference: van der Zijl NJ et al.(2011) Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial Diabetes Care 34: 845-851 [PMID: 21330640]

Interaction Information:

Comment At 26 weeks, valsartan, relative to placebo, resulted in a significant reduction in systolic and diastolic blood pressure and mean arterial pressure (MAP). Furthermore, 2-h postload glucose tended to increase after placebo treatment compared with valsartan treatment. Twenty-six weeks of treatment had no effect on BMI, waist circumference, FPG, HbA1c, FPI, and lipid metabolism.
Formal Description
Interaction-ID: 15487

drug/chemical compound

Valsartan

increases_activity of

Drugbank entries Show/Hide entries for Valsartan
Comment At 26 weeks, valsartan, relative to placebo, resulted in a significant reduction in systolic and diastolic blood pressure and mean arterial pressure (MAP). Furthermore, 2-h postload glucose tended to increase after placebo treatment compared with valsartan treatment. Twenty-six weeks of treatment had no effect on BMI, waist circumference, FPG, HbA1c, FPI, and lipid metabolism.
Formal Description
Interaction-ID: 15488

drug/chemical compound

Valsartan

NOT affects_activity of

Drugbank entries Show/Hide entries for Valsartan
Comment At 26 weeks, valsartan, relative to placebo, resulted in a significant reduction in systolic and diastolic blood pressure and mean arterial pressure (MAP). Furthermore, 2-h postload glucose tended to increase after placebo treatment compared with valsartan treatment. Twenty-six weeks of treatment had no effect on BMI, waist circumference, FPG, HbA1c, FPI, and lipid metabolism.
Formal Description
Interaction-ID: 15489

drug/chemical compound

Valsartan

NOT affects_quantity of

drug/chemical compound

Glucose

in blood; after fasting
Drugbank entries Show/Hide entries for Valsartan
Comment At 26 weeks, valsartan, relative to placebo, resulted in a significant reduction in systolic and diastolic blood pressure and mean arterial pressure (MAP). Furthermore, 2-h postload glucose tended to increase after placebo treatment compared with valsartan treatment. Twenty-six weeks of treatment had no effect on BMI, waist circumference, FPG, HbA1c, FPI, and lipid metabolism.
Formal Description
Interaction-ID: 15490

drug/chemical compound

Valsartan

NOT affects_quantity of

complex/PPI

Glycated hemoglobin

in blood
Drugbank entries Show/Hide entries for Valsartan
Comment At 26 weeks, valsartan, relative to placebo, resulted in a significant reduction in systolic and diastolic blood pressure and mean arterial pressure (MAP). Furthermore, 2-h postload glucose tended to increase after placebo treatment compared with valsartan treatment. Twenty-six weeks of treatment had no effect on BMI, waist circumference, FPG, HbA1c, FPI, and lipid metabolism.
Formal Description
Interaction-ID: 15491

drug/chemical compound

Valsartan

NOT affects_quantity of

complex/PPI

Insulin

in blood; after fasting
Drugbank entries Show/Hide entries for Valsartan
Comment At 26 weeks, valsartan, relative to placebo, resulted in a significant reduction in systolic and diastolic blood pressure and mean arterial pressure (MAP). Furthermore, 2-h postload glucose tended to increase after placebo treatment compared with valsartan treatment. Twenty-six weeks of treatment had no effect on BMI, waist circumference, FPG, HbA1c, FPI, and lipid metabolism.
Formal Description
Interaction-ID: 15492

drug/chemical compound

Valsartan

NOT affects_activity of

Drugbank entries Show/Hide entries for Valsartan
Comment Twenty-six weeks of valsartan treatment increased glucose-stimulated insulin release and insulin sensitivity in normotensive subjects with IGM. These findings may partly explain the beneficial effects of valsartan in the reduced incidence of type 2 diabetes.
Formal Description
Interaction-ID: 15493

drug/chemical compound

Valsartan

increases_activity of

after glucose stimulation
Drugbank entries Show/Hide entries for Valsartan
Comment Twenty-six weeks of valsartan treatment increased glucose-stimulated insulin release and insulin sensitivity in normotensive subjects with IGM. These findings may partly explain the beneficial effects of valsartan in the reduced incidence of type 2 diabetes.
Formal Description
Interaction-ID: 15504

drug/chemical compound

Valsartan

increases_activity of

Drugbank entries Show/Hide entries for Valsartan
Comment Twenty-six weeks of valsartan treatment increased glucose-stimulated insulin release and insulin sensitivity in normotensive subjects with IGM. These findings may partly explain the beneficial effects of valsartan in the reduced incidence of type 2 diabetes.
Formal Description
Interaction-ID: 15505

drug/chemical compound

Valsartan

decreases_activity of

Drugbank entries Show/Hide entries for Valsartan